Adlai Nortye Group Ltd. (ANL) Stock Price & Analysis
Adlai Nortye Group Ltd. (ANL) closed at USD 12.09 on Thursday, October 15, 2026, up 11.12% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.88; the Oct 15, 2026 session ranged USD 11.23–12.46 on volume of 864,143 shares. Market capitalization is $778.57M, with a 52-week range of USD 0.88–17.25 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANL.md
Key facts (ANL)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 29.5 (range 20–49).
- Total return with dividends: 1Y +650.9% vs S&P 500 +18.1%; 5Y -19.4% vs S&P 500 +85.1%.
Analysts (ANL)
Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 29.5 (low 20, high 49).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Jefferies | Initiated | Buy | $31 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-06-22 | Cantor Fitzgerald | Initiated | Overweight |
Total return (dividends reinvested) (ANL)
| 1Y (from 2025-10-16) | 5Y (from 2023-09-25) | |
|---|---|---|
| Total return | +650.9% | -19.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +656.1% | -6.8% |
| Volatility (annualized) | 133.8% | 126.2% |
| Max drawdown | -47.0% (Oct 2025→Dec 2025) | -93.3% (Sep 2023→Dec 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 12.09 |
|---|---|
| Change | ▲ 11.12% (up) |
| Previous Close | USD 10.88 |
| Open | USD 11.23 |
| Day Range | USD 11.23 – 12.46 |
| 52-Week Range | USD 0.88 – 17.25 |
| Volume | 864,143 shares |
| Market Cap | $778.57M |
| Exchange | NGM |
Technical Analysis (ANL)
Nexqual's technical model rates ANL "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.89 (neutral) |
| vs SMA50 | Below (USD 14.46) |
| MACD | -0.6 (negative) |
Analyst Ratings (ANL)
Wall Street analysts rate ANL "Buy" based on 7 analysts, with a mean price target of USD 29.5 (range USD 20–49), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 29.5 |
| High Target | USD 49 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (ANL)
| EPS Estimate | USD 0.03 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ANL)
| Total Revenue | $18.06M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -44.19% |
| Profit Margin | -124.77% |
| ROE | -20.23% |
| Debt / Equity | 0.12 |
| Current Ratio | 9.55 |
| Total Cash | $232.82M |
| Total Debt | $26.70M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ANL)
Nexqual rates Adlai Nortye Group Ltd.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $233M cash vs $27M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$34M (TTM) |
| Efficiency | Critical — ROE -20%, ROA -8.7% |
Ownership (ANL)
| Insider Ownership | +0.94% |
|---|---|
| Institutional Ownership | +41.33% |
| Shares Outstanding | 58.73M |
| Float | 49.57M |
| Short % of Float | +7.56% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ANL)
Adlai Nortye Group Ltd. is led by Yang Lu EMBA (age 46), Co- Founder, CEO & Chairman, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co- Founder, CEO & Chairman | Yang Lu EMBA (age 46) |
|---|---|
| President & Head of Research & Development | Ngai Chiu Tse (age 58) |
| Chief Financial Officer | Xiaofeng Ye (age 46) |
| Vice President of Operations | Zhiyong Yu |
Major Backers & Investors (ANL)
Notable institutional backers of Adlai Nortye Group Ltd. include Cormorant Asset Management, LP, Venrock Adviser, LLC, Balyasny Asset Management LP, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cormorant Asset Management, LP | 6.77% |
| Venrock Adviser, LLC | 5.47% |
| Balyasny Asset Management LP | 5.21% |
| Point72 Asset Management, L.P. | 3.64% |
| MPM Bioimpact LLC | 3.3% |
| Perceptive Advisors Llc | 3.05% |
| Casdin Capital, LLC | 2.13% |
| Adar1 Capital Management, LLC | 1.73% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt